Well no, this bad boy isn't a dividend payer, it's an investment stock. I've been holding this baby for about 15 years now. In fact, it's a story reality-deprived financially illiterate liberals should pay attention to.
After the human genome was mapped, pharma companies began exploring ways to use this knowledge to create new medicines. ISIS came up with an anti-sense technology, that would seek to fight disease at a genetic level. In its simplest terms, identifying genetic markers that allow diseases like cancer to grow in the body, and inhibit that marker from working with the cancer.
This year Isis became the first company to get a genetic-based drug to the market. In fact, it's the first drug Isis ever got on the market.
This is how pharma works. If you open a pharma company today, you can not expect to have a product on the shelves for a minimum of 10 years. And beyond that 10 years of research and development, your brand only has about 7 or 8 years of patent left to recoup the 10 years of R&D costs, cover the losses on 99% of compounds researched and developed that never make through FDA phase testing, and turn a profit. It's a monumental hill to climb.
Isis has passed the crest, and now I'm seeing a doubling of my initial investment. Although it took 15 years. But I see greater returns in the future.
Meanwhile, in the nations with their cutting edge socialist health care systems, what exciting new breakthroughs are their pharmaceutical industries making?